New heart implant could replace blood thinners for AFib patients

NCT ID NCT05224375

Completed Disease control Sponsor: Laminar, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested a device called the Laminar Left Atrial Appendage Closure System in 29 people with atrial fibrillation who cannot take blood thinners. The device is implanted to seal off a small pouch in the heart where clots often form. The goal was to see if it is safe and effective at reducing stroke risk without the need for long-term medication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Laminar Left Atrial Appendage Closure System (a device implanted to seal off part of the heart)
What this could lead to: If successful, this device could offer a long-term alternative to blood thinners for preventing strokes in people with atrial fibrillation.
What could go wrong: This was a small early study with only 29 participants, so results may not apply to everyone. There are risks like stroke, bleeding, or need for additional procedures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL FIBRILLATION

Contacts and locations

Locations

Tbilisi Heart and Vascular Clinic

Tbilisi, Georgia

More trials for these conditions

Other studies related to the condition(s) this trial covers.